[Federal Register Volume 69, Number 211 (Tuesday, November 2, 2004)]
[Notices]
[Pages 63540-63541]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-24385]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-04-0307]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Officer at (404) 498-1210 or send an e-mail 
to <a href="/cdn-cgi/l/email-protection#325d5f50725156511c555d44"><span class="__cf_email__" data-cfemail="a1ceccc3e1c2c5c28fc6ced7">[email protected]</span></a>. Send written comments to CDC Desk Officer, Human 
Resources and Housing Branch, New Executive Office Building, Room 
10235, Washington, DC 20503 or by fax to (202) 395-6974. Written 
comments should be received within 30 days of this notice.

Proposed Project

    Gonococcal Isolate Surveillance Project (GISP), OMB No. 0920-0307--
Revision--National Center for HIV, STD, and TB Prevention (NCHSTP), 
Centers for Disease Control and Prevention (CDC).
    CDC is requesting a 3-year approval/with change for this project. 
The objectives of GISP are to monitor trends in antimicrobial 
susceptibility of strains of Neisseria gonorrhoeae in the U.S. and 
characterize resistant isolates. GISP provides critical surveillance 
for antimicrobial resistance, allowing for informed treatment 
recommendations. This project began in 1986 as a voluntary surveillance 
project and has involved 5 regional laboratories and 30 publicly-
funded, sexually transmitted disease (STD) clinics around the country. 
The STD clinics submit up to 25 gonococcal isolates per month to the 
regional laboratories, which measure susceptibility to a panel of 
antibiotics. Limited demographic and clinical

[[Page 63541]]

information corresponding to the isolates are submitted directly by the 
STD clinics to CDC.
    During 1986-2003, GISP demonstrated the ability to effectively 
achieve its objectives. The emergence, in the U.S., of resistance to 
fluoroquinolones, commonly used therapies for gonorrhea, was identified 
through GISP and makes ongoing surveillance critical. Emergence of 
decreased susceptibility to fluoroquinolones among the men having sex 
with men (MSM) population in the U.S. was also identified through GISP 
in 2003. Data gathered through GISP were used to change the treatment 
for gonorrhea for the MSM population in April 2004. There are no costs 
to respondents other than their time. The estimated annualized burden 
for this data collection is 8,142 hours.

------------------------------------------------------------------------
                                                Number of      Average
                                  Number of     responses    burden per
          Respondent             respondents       per        response
                                               respondent    (in hours)
------------------------------------------------------------------------
Laboratory:
    Form 2....................             5          1368             1
    Form 3....................             5            48         12/60
Clinical personnel............            30           228         11/60
------------------------------------------------------------------------


    Dated: October 27, 2004.
B. Kathy Skipper,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 04-24385 Filed 11-1-04; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>